Stanhope R, Pringle P J, Brook C G
Endocrine Unit, Middlesex Hospital, London, U.K.
Acta Paediatr Scand. 1988 Jul;77(4):525-30. doi: 10.1111/j.1651-2227.1988.tb10694.x.
We have treated 14 girls with central precocious puberty for a mean period of 2.3 years (range, 0.5-3.9) with intranasal (D-Ser6) GnRH analogue administered in a mean dose of 28 micrograms/kg/day (range, 15-56). With the onset of treatment there was an initial increase in sitting height compared to subischial leg length, but overall there was no significant change in height standard deviation score for bone age. In this respect our results were indistinguishable from untreated children with central precocious puberty. There was a decrease in physiological GH secretion, associated with decreased sex steroid secretion, which probably accounts for the growth deceleration which has been described during GnRH analogue therapy. The effect of this growth deceleration combined with slowing of the rate of epiphyseal maturation may explain the absence of alteration in height prognosis.
我们用鼻内给予（D-Ser6）促性腺激素释放激素（GnRH）类似物治疗了14名中枢性性早熟女孩，平均治疗时间为2.3年（范围0.5 - 3.9年），平均剂量为28微克/千克/天（范围15 - 56微克/千克/天）。治疗开始时，坐高相对于坐骨下腿长有初始增加，但总体而言，骨龄的身高标准差评分无显著变化。在这方面，我们的结果与未治疗的中枢性性早熟儿童没有区别。生理生长激素（GH）分泌减少，伴有性类固醇分泌减少，这可能是GnRH类似物治疗期间所描述的生长减速的原因。这种生长减速与骨骺成熟速率减慢相结合的作用，可能解释了身高预后无改变的原因。
